Q1 Fiscal 2024 Capital Structure Review
01 F2024 STRATEGIC
HIGHLIGHTS
Completed planting first seed-based production grow room resulting from
strategic investment in US-based Phylos
• Advanced the second tranche of US$2.75 million to Phylos for a total current
investment of US$6.0 million in senior secured convertible loans due to early
achievement of THCV concentration and aroma milestones for F1 seeds
Completed first craft harvest resulting from the completed expansion of the
Company's Lac-Supérieur facility
• Product Development Collaboration with BAT moving rapidly toward product
commercialization. PK study for nano-emulsion gummy technology complete and
the Company is compiling and analyzing results to substantiate product claims
regarding onset and half-life
• Applied for EU-GMP certification of Moncton facility in November 2023 and
awaiting audit
•
⚫ Subsequent to Q1 F2024 announced shareholder approval and closing of first
$41.5 million tranche of $124.6 million follow-on investment from BAT and
creation of the Jupiter investment pool to increase Organigram's international
footprint
BAT
A BETTER TOMORROW
PHYLOS
76 BIOSCIENCE
GREENTANK
ORGANIGRAMView entire presentation